Cargando…

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer

BACKGROUND: The NOTCH signaling pathway may be involved in the survival of stem cell-like tumor-initiating cells and contribute to tumor growth. In this phase Ib, open-label, multicenter study (NCT01876251), we evaluated PF-03084014, a selective gamma-secretase inhibitor in patients with advanced tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Locatelli, Marzia A., Aftimos, Philippe, Dees, E. Claire, LoRusso, Patricia M., Pegram, Mark D., Awada, Ahmad, Huang, Bo, Cesari, Rossano, Jiang, Yuqiu, Shaik, M. Naveed, Kern, Kenneth A., Curigliano, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356802/ https://www.ncbi.nlm.nih.gov/pubmed/27906684 http://dx.doi.org/10.18632/oncotarget.13727

Ejemplares similares

Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
por: Yang, Xuran, et al.
Publicado: (2018)

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
por: Papayannidis, C, et al.
Publicado: (2015)

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
por: Arcaroli, J J, et al.
Publicado: (2013)

Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib
por: Zhang, Cathy C, et al.
Publicado: (2014)

HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro
por: Du, Zhongbo, et al.
Publicado: (2018)

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [(18)F]PF-06684511
por: Arakawa, Ryosuke, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies
por: Ahn, Jae Eun, et al.
Publicado: (2019)

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018)

Stalling secretase assembly
por: Williams, Ruth
Publicado: (2007)

Research advances and new challenges in overcoming triple-negative breast cancer
por: Zong, Yu, et al.
Publicado: (2021)

PK/PD model‐informed dose selection for oncology phase I expansion: Case study based on PF‐06939999, a PRMT5 inhibitor
por: Guo, Cen, et al.
Publicado: (2022)

Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site
por: Uemura, Kengo, et al.
Publicado: (2010)

Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer
por: Hossain, Fokhrul, et al.
Publicado: (2023)

Presenilin/γ-Secretase and Inflammation
por: Saura, Carlos A.
Publicado: (2010)

The biological function of β-secretase
por: Haass, Christian
Publicado: (2013)

Repression of Alzheimer's beta-Secretase
por: Liao, Francesca-Fang, et al.
Publicado: (2013)

γ-Secretase in Alzheimer’s disease
por: Hur, Ji-Yeun
Publicado: (2022)

Beneficial Effect of Antibodies against β- Secretase Cleavage Site of App on Alzheimer’s-Like Pathology in Triple-Transgenic Mice
por: Rabinovich-Nikitin, Inna, et al.
Publicado: (2012)

The Book of PF
por: Hansteen, Peter
Publicado: (2014)

γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not
por: Lessard, Christian B., et al.
Publicado: (2020)

γ‐Secretase modulators show selectivity for γ‐secretase–mediated amyloid precursor protein intramembrane processing
por: Weber, Tobias A., et al.
Publicado: (2021)

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2017)

ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
por: Hwang, Eunjoo, et al.
Publicado: (2018)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Gamma-secretase: from pathogenesis to therapeutics
por: Li, Yueming
Publicado: (2012)

Structure-function relationship of γ-secretase
por: Tomita, Taisuke
Publicado: (2012)

Gamma secretase inhibitors of Notch signaling
por: Olsauskas-Kuprys, Roma, et al.
Publicado: (2013)

Secretases: potential and roadblocks on the way to therapy
por: De Strooper, Bart
Publicado: (2013)

Endogenous and exogenous regulation of gamma-secretase
por: Li, Yueming
Publicado: (2013)

The dynamic conformational landscape of γ-secretase
por: Elad, Nadav, et al.
Publicado: (2015)

Presenilins and γ-Secretase in Membrane Proteostasis
por: Oikawa, Naoto, et al.
Publicado: (2019)

The emerging role of β-secretases in cancer
por: Farris, Francesco, et al.
Publicado: (2021)

The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition
por: Han, Jianxun, et al.
Publicado: (2009)

Complex Relationships between Substrate Sequence and Sensitivity to Alterations in γ-Secretase Processivity Induced by γ-Secretase Modulators
por: Jung, Joo In, et al.
Publicado: (2014)

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses
por: Azzam, Diana J, et al.
Publicado: (2013)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Misclassification of PfEH1 and PfEH2 as Epoxide Hydrolases
por: Arand, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rdfiab35213bjp35h04h1io4tl